Impact of the COVID-19 pandemic on the performance of selected cardiac electrotherapy and electrophysiology procedures
Jerzy Krzysztof Wranicz(Medical University of Lodz), Krzysztof Kaczmarek(Medical University of Lodz), Jarosław Dróżdż(Copenhagen University Hospital), Grzegorz Piotrowski(Copernicus Memorial Hospital), Monika Różycka-Kosmalska(Medical University of Lodz), Paweł Ptaszyński(Medical University of Lodz), Jarosław D. Kasprzak(Medical University of Lodz), Tomasz Ciuruś(Nicolaus Copernicus University), Andrzej Lubiński(Medical University of Lodz), P Zycinski(Nicolaus Copernicus University), Marcin Kosmalski(Medical University of Lodz)
Cited by 7
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
EAE/ASE Recommendations for Image Acquisition and Display Using Three-Dimensional Echocardiography
|Journal of the American Society of Echocardiography|2011|1.1k
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889
Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
|New England Journal of Medicine|2011|877
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-Year Follow-Up Outcomes and Differences Across Regions
|European Journal of Heart Failure|2016|781